BioLineRx Ltd. (NASDAQ:BLRX) Q1 2020 Earnings Conference Call May 20, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical Development Ella Sorani - Vice President, Research and Development Conference Call Participants Joe Pantginis - H.C. Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the ...

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2019 Earnings Conference Call March 12, 2020 10:00 AM ET Company Participants Timothy McCarthy - Investor Relations, LifeSci Advisors Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Abi Vainstein - Vice President, Clinical Development Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx's Fourth Quarter and Full Year 2019 Confere ...

As filed with the U.S. Securities and Exchange Commission on March 12, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY ...

BioLineRx Ltd. (NASDAQ:BLRX) Q3 2019 Results Earnings Conference Call November 11, 2019 10:00 AM ET Company Participants Timothy McCarthy - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Conference Call Participants Joe Pantginis - HC Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Third Quarter 2019 Conference Call. All participants are at present in a listen-only mode. Fol ...

BioLineRx Ltd. (NASDAQ:BLRX) Q2 2019 Results Conference Call August 6, 2019 10:00 AM ET Company Participants Timothy McCarthy - IR, LifeSci Advisors Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Conference Call Participants Mark Breidenbach - Oppenheimer Joe Pantginis - HC Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Second Quarter 2019 Conference Call. All participants are at present in a listen-only mode. Following mana ...

BioLineRx Ltd. (NASDAQ:BLRX) Q1 2019 Results Earnings Conference Call May 14, 2019 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical Development Ella Sorani - VP, Research and Development Conference Call Participants Joe Pantginis - HC Wainwright Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2019 Conference Call. [Operator Instructions] I would now like to turn the call over ...

BioLineRx Ltd. (NASDAQ:BLRX) Q4 2018 Earnings Conference Call March 27, 2019 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Ella Sorani - VP, Research and Development Conference Call Participants Jason McCarthy - Maxim Joe Pantginis - HC Wainwright Mark Breidenbach - Oppenheimer Operator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2018 Results C ...

As filed with the U.S. Securities and Exchange Commission on March 28, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY ...